MedTrace Logo

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01281917 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-12-13

Study results available
· View outcomes & findings →

Summary

The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.

Conditions

  • Non-Hodgkins Lymphoma

Interventions

DRUG

Velcade

Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)

DRUG

Temsirolimus

Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Brad S Kahl, MD · Universtity of Wisconsin- Madison

  • Timothy S Fenske, MD · Medical College of Wisconsin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-10-31
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281917 on ClinicalTrials.gov